Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Denied an Immune Checkpoint Inhibitor as Not Medically Necessary — and How to Appeal

A medical-necessity denial from UnitedHealthcare for a checkpoint inhibitor — pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), or cemiplimab (Libtayo) — typically means that the documentation submitted with the prior authorization request did not satisfy one or more clinical criteria in UHC's coverage determination policy. This may involve missing biomarker results, an undocumented line-of-therapy requirement, an incomplete diagnosis code, or a gap between the submitted records and the specific criteria in UHC's policy. It does not necessarily mean your treating oncologist's judgment is wrong — it frequently means the administrative record needs to be strengthened.

## Why This Denial Is Appealable

Medical-necessity denials are the most commonly appealed and among the most frequently overturned category of health insurance denials. The denial notice must identify the specific criterion that was not met. If it does not, request the full written rationale and the clinical policy applied. Under ERISA §503, self-funded employer plans must provide a full and fair review, including the right to submit additional clinical evidence. Under ACA §2719, insured plans must allow independent external review by a qualified oncologist.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice — typically 180 days from the EOB date for non-urgent cases. UHC must decide within 30 days for standard pre-service appeals.
• Expedited review: If your condition is urgent or you are currently receiving treatment, request expedited internal review (72-hour decision) and simultaneously request external review.
• External review (ACA §2719): After one internal denial, you may escalate to independent external review. Request a reviewer with oncology expertise matched to your cancer type.
• State insurance department: File a complaint with your state insurance commissioner at any stage to create a regulatory record and potentially prompt a faster resolution.

## Documentation to Gather

• Complete diagnosis documentation: Pathology report, stage, histology, tumor type, and any molecular or genomic testing results relevant to the indication.
• Biomarker / companion diagnostic results: For checkpoint inhibitors, the FDA-approved prescribing information often specifies a companion diagnostic requirement (e.g., PD-L1 expression level, MSI/dMMR status, TMB). Obtain the actual lab report and confirm it meets the criteria stated in the FDA label — your oncologist can confirm which result applies.
• Line-of-therapy documentation: Chart notes and treatment summaries documenting prior therapies, dates, and outcomes, establishing the correct line of therapy for the requested agent.
• Oncologist letter of medical necessity: A comprehensive letter citing the FDA-approved indication, the applicable NCCN guideline recommendation, your specific tumor characteristics, why the requested agent is appropriate, and why alternatives are not equally effective.
• Performance status and clinical severity documentation: Chart notes reflecting ECOG or Karnofsky performance status, organ function, and other clinical parameters relevant to the coverage criteria.

## Criteria-Mapping Structure

Request UHC's full clinical coverage policy and map every criterion to a chart fact:

| UHC Medical Necessity Criterion | Supporting Documentation | |---|---| | Confirmed diagnosis + histology | Pathology report | | Companion diagnostic result | Lab report with result | | Correct line of therapy | Treatment summary with prior therapies | | Performance status documented | Chart note | | NCCN/guideline support | Oncologist letter with category citation | | No equally effective covered alternative | Oncologist letter addressing alternatives |